Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2024 Jul 9;30(8):2374. doi: 10.1038/s41591-024-03175-4

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Franck Morschhauser 1,, Saurabh Dahiya 2,3, M Lia Palomba 4, Alejandro Martin Garcia-Sancho 5, Juan Luis Reguera Ortega 6, John Kuruvilla 7, Ulrich Jäger 8, Guillaume Cartron 9, Koji Izutsu 10, Martin Dreyling 11, Brad Kahl 12, Hervé Ghesquieres 13, Kirit Ardeshna 14, Hideki Goto 15, Anna Maria Barbui 16, Jeremy S Abramson 17, Peter Borchmann 18, Isabelle Fleury 19, Stephan Mielke 20, Alan Skarbnik 21, Sven de Vos 22, Manali Kamdar 23, Reem Karmali 24, Andreas Viardot 25, Thalia Farazi 26, Omotayo Fasan 27, James Lymp 28, Min Vedal 28, Rina Nishii 27, Ariel Avilion 28, Jessica Papuga 29, Jinender Kumar 27, Loretta J Nastoupil 30
PMCID: PMC11333276  PMID: 38982297

Correction to: Nature Medicine 10.1038/s41591-024-02986-9, published online 3 June 2024.

In the version of the article initially published, in the Japan row of Supplementary Fig. 2, the values for the columns “Evaluable patients” and “Patients with ORR” were originally both 8 but have now been amended to 9. A corrected Supplementary Information file has now been uploaded online.


Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES